<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, Khan NA, Herman RJ, Bacon SL, Cloutier L, Dawes M, Rabkin SW, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Feldman RD, Lindsay P, Hill MD, Gelfer M, Burns KD, Vallee M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Sharma M, Reid DJ, Tobe SW, Poirier L, Padwal RS, Canadian Hypertension Education Program. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013 May;29(5):528-42. [38 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23541660&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Daskalopoulou SS, Khan NA, Quinn RR, et al. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2012;28:270-87.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Chronic kidney disease, unspecified  (585.9); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diagnostic ultrasound of heart  (88.72); Electrocardiogram  (89.52); End stage renal disease  (585.6); General physical examination  (89.7); Heart failure, unspecified  (428.9); Hyperaldosteronism, unspecified  (255.10); Loss of weight  (783.21)"/><FieldValue Value="MSH: Adrenergic alpha-Antagonists ; Adrenergic beta-Antagonists ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Aspirin ; Blood Chemical Analysis ; Blood Pressure Determination ; Blood Pressure Monitoring, Ambulatory ; Calcium Channel Blockers ; Coronary Artery Disease ; Diabetes Mellitus ; Diet Therapy ; Diet, Sodium-Restricted ; Dietary Supplements ; Drug Therapy, Combination ; Echocardiography ; Electrocardiography ; Exercise ; Follow-Up Studies ; Goals ; Heart Failure ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hyperaldosteronism ; Hypertension ; Hypertension, Renovascular ; Hypertrophy, Left Ventricular ; Kidney Failure, Chronic ; Medical History Taking ; Myocardial Ischemia ; Patient Compliance ; Patient Education as Topic ; Pheochromocytoma ; Physical Examination ; Renal Insufficiency, Chronic ; Risk Assessment ; Sodium Chloride Symporter Inhibitors ; Stroke ; Urinalysis ; Weight Loss "/><FieldValue Value="MTH: Adrenergic alpha-Antagonists ; Adrenergic beta-Antagonists ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Aspirin ; Blood Chemical Analysis ; Blood potassium measurement ; Blood pressure determination ; Blood sodium measurement ; Body Weight decreased ; Calcium Channel Blockers ; Cerebrovascular accident ; Chronic Kidney Diseases ; Chronic Kidney Insufficiency ; Combination Drug Therapy ; Compliance behavior ; Coronary Artery Disease ; Creatinine measurement ; Diabetes Mellitus ; Diet therapy ; Dietary Supplements ; Echocardiography ; Electrocardiography ; Exercise ; Fasting blood glucose measurement ; follow-up ; Heart failure ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypertensive disease ; Kidney Failure, Chronic ; Left Ventricular Hypertrophy ; Low sodium diet ; Myocardial Ischemia ; objective (goal) ; Patient education (procedure) ; Pheochromocytoma ; physical examination ; Risk Assessment ; Sodium Chloride Symporter Inhibitors ; Thiazide Diuretics ; urinalysis ; Urine albumin measurement "/><FieldValue Value="PDQ: acetylsalicyclic acid "/><FieldValue Value="SNOMEDCT_US: Alpha-adrenergic blocking agent  (373275009); Alpha-adrenergic blocking agent  (67440007); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Aspirin  (387458008); Aspirin  (7947003); Assessment for risk of cardiovascular disease  (441829007); beta-Blocking agent  (33252009); beta-Blocking agent  (373254001); Blood chemistry  (166312007); Blood potassium measurement  (312468003); Blood pressure taking  (46973005); Calcium channel blocker  (373304005); Calcium channel blocker  (48698004); Cerebrovascular accident  (230690007); Chronic renal impairment  (236425005); Compliance behavior  (405078008); Creatinine measurement  (70901006); Diabetes mellitus  (73211009); Disorder of coronary artery  (414024009); Echocardiography  (40701008); Education about alcohol consumption  (281078001); Electrocardiographic procedure  (29303009); End stage renal disease  (46177005); End stage renal disease  (90688005); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fasting blood glucose measurement  (271062006); Fasting lipid profile  (252150008); Goal  (410518001); Heart failure  (84114007); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Hyperaldosteronism  (88213004); Hypertension education  (39155009); Hypertensive disorder  (38341003); Hypotensive agent  (1182007); Hypotensive agent  (372586001); Left ventricular hypertrophy  (55827005); Lifestyle education regarding hypertension  (443402002); Low sodium diet  (386619000); Low sodium diet  (437421000124105); Myocardial ischemia  (414545008); Myocardial ischemia  (414795007); Nutritional supplement  (108961000); Nutritional supplement  (226279009); Nutritional supplement  (373453009); Patient education  (311401005); Pheochromocytoma  (302835009); Pheochromocytoma  (399343007); Pheochromocytoma  (85583005); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Renovascular hypertension  (123799005); Risk assessment  (225338004); Secondary hypertension  (31992008); Sodium measurement, blood  (312469006); Stress management  (226060000); Stress management  (441151000124104); Systolic hypertension  (56218007); Thiazide diuretic  (372747003); Thiazide diuretic  (45518007); Urinalysis  (167217005); Urinalysis  (27171005); Urine albumin measurement  (271000000); Weight decreased  (161832001); Weight decreased  (262285001); Weight decreased  (89362005)"/><FieldValue Value="UMD: Scanning Systems, Ultrasonic, Cardiac  (17-422)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Hypertension, including hypertension associated with the following diseases or conditions:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ischemic heart disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Left ventricular hypertrophy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Nondiabetic chronic kidney disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Renovascular disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diabetes mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Endocrine causes such as hyperaldosteronism and pheochromocytoma &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Emergency Medicine" /><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nephrology" /><FieldValue Value="Preventive Medicine" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Allied Health Personnel" /><FieldValue Value="Dietitians" /><FieldValue Value="Nurses" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Public Health Departments" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To provide annually updated evidence-based recommendations for the prevention, diagnosis, assessment, and treatment of hypertension in adults for 2013&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Canadian adult population with or at risk for hypertension, including patients with hypertension associated with ischemic heart disease, heart failure, stroke, left ventricular hypertrophy, nondiabetic kidney disease, renovascular disease, diabetes mellitus, and secondary hypertension due to endocrine causes such as hyperaldosteronism and pheochromocytoma&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: These recommendations focus on adult care and are predominantly targeted toward primary care providers. For issues related to the diagnosis and evaluation of high blood pressure in children and adolescents, the reader is referred to separate guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Evaluation/Risk Assessment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Accurate measurement of blood pressure (BP) to determine cardiovascular risk and monitor antihypertensive treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of criteria for diagnosis of hypertension &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;History, physical examination, and diagnostic tests to search for target organ damage &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of office, home, or ambulatory BP measurements &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Investigations for secondary causes of hypertension in patients with suggestive clinical and/or laboratory features &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Follow-up intervals based on BP readings and target organ damage &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment of overall cardiovascular risk in hypertensive patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Routine and optional laboratory tests for the investigation of patients with hypertension&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Urinalysis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Blood chemistry (potassium, sodium, and creatinine) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Fasting blood glucose &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Fasting serum total cholesterol and high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Standard 12-lead electrocardiography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Urinary albumin excretion in patients with diabetes &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitoring for new appearance of diabetes &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assessment for renovascular hypertension &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening for and diagnosis of hyperaldosteronism &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening for and diagnosis of pheochromocytoma &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Echocardiography for evaluation of left ventricular dysfunction or coronary artery disease &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Prevention/Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Health behaviour management&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Physical exercise &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Weight reduction &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Limited alcohol consumption &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dietary Approaches to Stop Hypertension (DASH) diet &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reduction in dietary sodium intake &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Supplemental potassium, calcium, magnesium (not recommended) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Stress management &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antihypertensive therapy for adults without compelling indications for specific agents&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Thiazide diuretic &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&amp;beta;-blocker &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Angiotensin-converting enzyme (ACE) inhibitor &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Long-acting calcium channel blocker (CCB) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Angiotensin-receptor blocker (ARB) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;&amp;alpha;-blocker &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monotherapy or combination therapy &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Therapy for isolated systolic hypertension &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Global vascular protection therapy for adults without compelling indications for specific agents (statin therapy, low-dose acetylsalicylic acid) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Setting systolic and diastolic BP goals &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hypertension in association with ischemic heart disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hypertension in association with heart failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hypertension in association with stroke &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hypertension in association with left ventricular hypertrophy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hypertension in association with nondiabetic chronic kidney disease (CKD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hypertension in association with renovascular disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hypertension in association with diabetes mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adherence strategies for patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of secondary hypertension due to endocrine causes &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular morbidity and mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Total mortality outcomes &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood pressure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Progressive renal impairment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fatal or non-fatal stroke &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A systematic literature search was performed by a Cochrane Collaboration librarian in MEDLINE/PubMed, as well as PsycINFO for the Adherence section, using text words and MeSH headings. Search terms included hypertension [MeSH], hypertens*[ti, ab], and blood pressure; these were combined with topic-specific terms to generate search results for each subgroup to review. The search is current to August 2012. Bibliographies of identified articles were also manually searched (details of search strategies and retrieved articles are available upon request). Randomized controlled trials and systematic reviews of randomized trials were reviewed for treatment recommendations and cross-sectional and cohort studies were reviewed for assessing diagnosis and prognosis.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /><FieldValue Value="Weighting According to a Rating Scheme (Scheme Not Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;See the Rating Scheme for the Strength of the Recommendations&quot; field.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Studies that included relevant outcomes were selected for further review. Cardiovascular morbidity and mortality and total mortality outcomes were prioritized. For health behavior recommendations, blood pressure was considered an acceptable surrogate and, in patients with chronic kidney disease (CKD), progressive renal impairment was considered to be a clinically important outcome. Study characteristics and study quality were assessed using prespecified, standardized algorithms developed by the Canadian Hypertension Education Program (CHEP) for critical appraisal of randomized controlled trials and cohort studies.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus (Consensus Development Conference)" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Canadian Hypertension Education Program (CHEP) Recommendations Task Force is a multidisciplinary panel comprised of 2 co-chairs and 23 subgroups. Subgroup members, considered content experts in their fields, were responsible for reviewing annual search results and, if indicated, drafting new recommendations or proposing changes to old recommendations. An independent central review committee of methodology experts who had no industry affiliations separately reviewed, graded, and refined proposed recommendations, which were then presented at a 1-day consensus conference in Toronto. Members of the Canadian Task Force on Preventive Health Care, Canadian Diabetes Association Guidelines Committee, Canadian Society of Nephrology, Canadian Stroke Network, and the Canadian Cardiovascular Harmonized National Guideline Endeavour Initiative also collaborated with CHEP subgroup members to ensure harmonization of recommendations between organizations. Existing CHEP recommendations are annually updated and relevant emerging hypertension issues identified by CHEP members and the target population (health care providers) are reviewed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Recommendations were graded according to the strength of their underlying evidence (for details, see the &quot;Rating Scheme for the Strength of the Recommendations&quot; field), ranging from Grade A (strongest evidence, based on high-quality randomized clinical trials) to Grade D (weakest evidence, based on low power, imprecise studies or expert opinion alone).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The recommendations process is in accord with the Appraisal of Guidelines for Research and Evaluation (AGREE) II guidelines and has been externally reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grading Scheme for Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grading Scheme for Recommendations&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendations are based on randomized trials (or systematic reviews of trials) with high levels of internal validity and statistical precision, and for which the study results can be directly applied to patients because of similar clinical characteristics and the clinical relevance of the study outcomes.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendations are based on randomized trials, systematic reviews or prespecified subgroup analyses of randomized trials that have lower precision, or there is a need to extrapolate from studies because of differing populations or reporting of validated intermediate/surrogate outcomes rather than clinically important outcomes.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendations are based on trials that have lower levels of internal validity and/or precision, or trials reporting unvalidated surrogate outcomes, or results from non-randomized observational studies.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendations are based on expert opinion alone.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;After the consensus meeting, proposed recommendations were finalized and submitted to all 62 voting members of the Canadian Hypertension Education Program (CHEP) Evidence-Based Recommendations Task Force for approval. Members with potential conflicts of interest recused themselves from voting on specific recommendations. Recommendations receiving more than 70% approval were passed. This year, both newly proposed recommendations received at least 80% approval.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions for the strength of the recommendations (&lt;strong&gt;A-D&lt;/strong&gt;) are provided at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Diagnosis and Assessment&lt;/span&gt;&lt;/strong&gt; &lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Accurate Measurement of Blood Pressure (BP)&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Health care professionals who have been specifically trained to measure BP accurately should assess BP in all adult patients at all appropriate visits to determine cardiovascular risk and monitor antihypertensive treatment (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Use of standardized measurement techniques (see Supplemental Table S2 [see the &quot;Availability of Companion Documents&quot; field]) is recommended when assessing BP (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Automated office BP measurement (OBPM) can be used in the assessment of office BP (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;When used in proper conditions, automated office systolic blood pressure (SBP) of &amp;ge;135 mm Hg or diastolic blood pressure (DBP) of &amp;ge;85 mm Hg should be considered analogous to mean awake ambulatory SBP of &amp;ge;135 mm Hg and DBP of &amp;ge;85 mm Hg, respectively (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Criteria for Diagnosis of Hypertension and Recommendations for Follow-up&lt;/strong&gt; (see Figure 1 in the original guideline document)&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;At initial presentation, patients demonstrating features of a hypertensive urgency or emergency (see Supplemental Table S3 in the original guideline document) should be diagnosed as hypertensive and require immediate management (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If SBP is &amp;ge;140 mm Hg and/or DBP is &amp;ge;90 mm Hg, a specific visit should be scheduled for the assessment of hypertension (&lt;strong&gt;Grade D&lt;/strong&gt;). If BP is high-normal (SBP 130-139 mm Hg and/or DBP 85-89 mm Hg), annual follow-up is recommended (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;At the initial visit for the assessment of hypertension, if SBP is &amp;ge;140 and/or DBP is &amp;ge;90 mm Hg, more than 2 additional readings should be taken during the same visit using a validated device and according to the recommended procedure for accurate BP determination (see Supplemental Table S2 [see the &quot;Availability of Companion Documents&quot; field]). The first reading should be discarded and the latter 2 readings averaged. A history and physical examination should be performed and, if clinically indicated, diagnostic tests to search for target organ damage (see Supplemental Table S4 [see the &quot;Availability of Companion Documents&quot; field]) and associated cardiovascular risk factors (see Supplemental Table S5 [see the &quot;Availability of Companion Documents&quot; field]) should be arranged within 2 visits. Exogenous factors that can induce or aggravate hypertension should be assessed and removed if possible (See supplemental Table S6 in the original guideline document). Visit 2 should be scheduled within 1 month (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;At visit 2 for the assessment of hypertension, patients with macrovascular target organ damage, diabetes mellitus, or chronic kidney disease (CKD) (glomerular filtration rate &amp;lt;60 mL per minute per 1.73 m&lt;sup&gt;2&lt;/sup&gt;) can be diagnosed as hypertensive if SBP is &amp;ge;140 mm Hg and/or DBP is &amp;ge;90 mm Hg (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;At visit 2 for the assessment of hypertension, patients without macrovascular target organ damage, diabetes mellitus, or CKD can be diagnosed as hypertensive if the SBP is &amp;ge;180 mm Hg and/or the DBP is &amp;ge;110 mm Hg (&lt;strong&gt;Grade D&lt;/strong&gt;). Patients without macrovascular target organ damage, diabetes mellitus, or CKD but with lower BP levels should undergo further evaluation using any of the 3 approaches outlined next:&#xD;&#xA;        &lt;ol style=&quot;list-style-type: lower-roman;&quot;&gt;&#xD;&#xA;            &lt;li&gt;&lt;strong&gt;OBPM&lt;/strong&gt;: Using manual OBPM, patients can be diagnosed as hypertensive if the SBP is &amp;ge;160 mm Hg or the DBP is &amp;ge;100 mm Hg averaged across the first 3 visits, or if the SBP averages &amp;ge;140 mm Hg or the DBP averages &amp;ge;90 mm Hg averaged across 5 visits (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;&lt;strong&gt;Ambulatory BP measurement (ABPM)&lt;/strong&gt;: Using ABPM (see Recommendations in section VIII. ABPM below), patients can be diagnosed as hypertensive if the mean awake SBP is &amp;ge;135 mm Hg or the DBP is &amp;ge;85 mm Hg or if the mean 24-hour SBP is &amp;ge;130 mm Hg or the DBP is &amp;ge; 80 mm Hg (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;&lt;strong&gt;Home BP monitoring (HBPM)&lt;/strong&gt;: Using HBPM (see Recommendations in section VII. HBPM below), patients can be diagnosed as hypertensive if the average SBP is &amp;ge;135 mm Hg or the DBP is &amp;ge;85 mm Hg (&lt;strong&gt;Grade C&lt;/strong&gt;). If the average home BP is &amp;lt;135/85 mm Hg, it is advisable to either repeat home monitoring to confirm the home BP is &amp;lt;135/85 mm Hg or perform 24-hour ABPM to confirm that the mean 24-hour ABPM is &amp;lt;130/80 mm Hg and the mean awake ABPM is &amp;lt;135/85 mm Hg before diagnosing white coat hypertension (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;        &lt;li&gt;Investigations for secondary causes of hypertension should be initiated in patients with suggestive clinical and/or laboratory features (outlined in sections V and VI below) (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If at the last diagnostic visit the patient is not diagnosed as hypertensive and has no evidence of macrovascular target organ damage, the patient's BP should be assessed at yearly intervals (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hypertensive patients receiving lifestyle modification advice alone (nonpharmacological treatment) should be followed up at 3- to 6-month intervals. Shorter intervals (every 1 or 2 months) are needed for patients with higher BPs (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients taking antihypertensive drugs should be seen monthly or every 2 months, depending on the level of BP, until readings on 2 consecutive visits are below their target (&lt;strong&gt;Grade D&lt;/strong&gt;). Shorter intervals between visits will be needed for symptomatic patients and those with severe hypertension, intolerance to antihypertensive drugs, or target organ damage (&lt;strong&gt;Grade D&lt;/strong&gt;). When the target BP has been reached, patients should be seen at 3- to 6-month intervals (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Assessment of Overall Cardiovascular Risk in Hypertensive Patients&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Global cardiovascular risk should be assessed. Multifactorial risk assessment models can be used to predict more accurately an individual's global cardiovascular risk (&lt;strong&gt;Grade A&lt;/strong&gt;) and to use antihypertensive therapy more efficiently (&lt;strong&gt;Grade D&lt;/strong&gt;). In the absence of Canadian data to determine the accuracy of risk calculations, avoid using absolute levels of risk to support treatment decisions (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consider informing patients of their global risk to improve the effectiveness of risk-factor modification (&lt;strong&gt;Grade B&lt;/strong&gt;). Consider also using analogies that describe comparative risk such as &quot;cardiovascular age,&quot; &quot;vascular age,&quot; or &quot;heart age&quot; to inform patients of their risk status (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Routine and Optional Laboratory Tests for the Investigation of Patients with Hypertension&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Routine laboratory tests that should be performed for the investigation of all patients with hypertension include the following:&#xD;&#xA;        &lt;ol style=&quot;list-style-type: lower-roman;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Urinalysis (&lt;strong&gt;Grade D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Blood chemistry (potassium, sodium, and creatinine) (&lt;strong&gt;Grade D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Fasting blood glucose (&lt;strong&gt;Grade D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Fasting serum total cholesterol and high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides (&lt;strong&gt;Grade D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Standard 12-lead electrocardiography (&lt;strong&gt;Grade C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;        &lt;li&gt;Assess urinary albumin excretion in patients with diabetes (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;All treated hypertensive patients should be monitored according to the current Canadian Diabetes Association guidelines for the new appearance of diabetes (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;During the maintenance phase of hypertension management, tests (including those for electrolytes, creatinine, and fasting lipids) should be repeated with a frequency reflecting the clinical situation (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Assessment for Renovascular Hypertension&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Patients presenting with &amp;ge;2 of the clinical clues listed next, suggesting renovascular hypertension, should be investigated (&lt;strong&gt;Grade D&lt;/strong&gt;):&#xD;&#xA;        &lt;ol style=&quot;list-style-type: lower-roman;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Sudden onset or worsening of hypertension and age &amp;gt;55 or &amp;lt;30 years &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Presence of an abdominal bruit &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Hypertension resistant to &amp;ge;3 drugs &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Rise in serum creatinine level &amp;ge;30% associated with use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Other atherosclerotic vascular disease, particularly in patients who smoke or have dyslipidemia &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Recurrent pulmonary edema associated with hypertensive surges. When available, the following tests are recommended to aid in the usual screening for renal vascular disease: captopril-enhanced radioisotope renal scan, Doppler sonography, magnetic resonance angiography, and computer tomography angiography (for those with normal renal function) (&lt;strong&gt;Grade B&lt;/strong&gt;). Captopril-enhanced radioisotope renal scan is not recommended for those with CKD (glomerular filtration rate &amp;lt;60 mL per minute per 1.73 m&lt;sup&gt;2&lt;/sup&gt;) (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Endocrine Hypertension&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Hyperaldosteronism: Screening and Diagnosis&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;Screening for hyperaldosteronism should be considered for the following patients (&lt;strong&gt;Grade D&lt;/strong&gt;):&#xD;&#xA;            &lt;ol style=&quot;list-style-type: lower-roman;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Hypertensive patients with spontaneous hypokalemia (K&lt;sup&gt;+&lt;/sup&gt; &amp;lt;3.5 mmol/L) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Hypertensive patients with marked diuretic-induced hypokalemia (K&lt;sup&gt;+&lt;/sup&gt; &amp;lt;3.0 mmol/L) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Patients with hypertension refractory to treatment with &amp;ge;3 drugs &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Hypertensive patients found to have an incidental adrenal adenoma &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;            &lt;li&gt;Screening for hyperaldosteronism should include assessment of plasma aldosterone and plasma renin activity (see Supplemental Table S7 [see the &quot;Availability of Companion Documents&quot; field]). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For patients with suspected hyperaldosteronism (on the basis of the screening test, see Supplemental Table S7, Item iii [see the &quot;Availability of Companion Documents&quot; field]), a diagnosis of primary aldosteronism should be established by demonstrating inappropriate autonomous hypersecretion of aldosterone using at least 1 of the maneuvers listed in Supplemental Table S7, Item iv (see the &quot;Availability of Companion Documents&quot; field). When the diagnosis is established, the abnormality should be localized using any of the tests described in Supplemental Table S7, Item v (see the &quot;Availability of Companion Documents&quot; field). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Pheochromocytoma: Screening and Diagnosis&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;If pheochromocytoma is strongly suspected, the patient should be referred to a specialized hypertension center, particularly if biochemical screening tests (See supplemental Table S8 in the original guideline document) have already been found to be positive (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;The following patients should be considered for screening for pheochromocytoma (&lt;strong&gt;Grade D&lt;/strong&gt;):&#xD;&#xA;            &lt;ol style=&quot;list-style-type: lower-roman;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Patients with paroxysmal and/or severe (BP &amp;ge;180/110 mm Hg) sustained hypertension refractory to usual antihypertensive therapy &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Patients with hypertension and multiple symptoms suggestive of catecholamine excess (e.g., headaches, palpitations, sweating, panic attacks, and pallor) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Patients with hypertension triggered by &amp;beta;-blockers, monoamine oxidase inhibitors, micturition, or changes in abdominal pressure &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Patients with incidentally discovered adrenal mass and patients with hypertension and multiple endocrine neoplasia 2A or 2B, von Recklinghausen's neurofibromatosis, or von Hippel-Lindau disease &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;For patients with positive biochemical screening tests, localization of pheochromocytomas should involve the use of magnetic resonance imaging (preferable), computed tomography (if magnetic resonance imaging is unavailable), and/or iodine I-131 meta-iodobenzylguanidine scintigraphy (&lt;strong&gt;Grade C for each modality&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;/ol&gt;&#xD;&#xA;            &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;7&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;HBPM&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;HBPM can be used in the diagnosis of hypertension (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The use of HBPM on a regular basis should be considered for patients with hypertension, particularly those with:&#xD;&#xA;        &lt;ol style=&quot;list-style-type: lower-roman;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Diabetes mellitus (&lt;strong&gt;Grade D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;CKD (&lt;strong&gt;Grade C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Suspected nonadherence (&lt;strong&gt;Grade D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Demonstrated white coat effect (&lt;strong&gt;Grade C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;BP controlled in the office but not at home (masked hypertension) (&lt;strong&gt;Grade C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;        &lt;li&gt;When white coat hypertension is suggested by HBPM, its presence should be confirmed by repeat HBPM (see Recommendation 8 in this section) or ABPM before treatment decisions are made (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients should be advised to purchase and use only HBPM devices that are appropriate for the individual and have met standards of the Association for the Advancement of Medical Instrumentation, the most recent requirements of the British Hypertension Society protocol, or the International Protocol for validation of automated BP measuring devices. Patients should be encouraged to use devices with data recording capabilities or automatic data transmission to increase the reliability of reported HBPM (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Home SBP values &amp;ge;135 mm Hg or DBP values &amp;ge;85 mm Hg should be considered elevated and associated with an increased overall mortality risk analogous to office SBP readings of &amp;ge;140 mm Hg or DBP &amp;ge;90 mm Hg (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Health care professionals should ensure that patients who measure their BP at home have adequate training and, if necessary, repeat training in measuring their BP. Patients should be observed to determine that they measure BP correctly and should be given adequate information about interpreting these readings (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The accuracy of all individual patients' validated devices (including electronic devices) must be regularly checked against a device of known calibration (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;HBPM for assessing white coat hypertension or sustained hypertension should be based on duplicate measures, morning and evening, for an initial 7-day period. First-day home BP values should not be considered (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;8&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;ABPM&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;ABPM can be used in the diagnosis of hypertension (&lt;strong&gt;Grade C&lt;/strong&gt;). ABPM should be considered when an office-induced increase in BP is suspected in treated patients with:&#xD;&#xA;        &lt;ol style=&quot;list-style-type: lower-roman;&quot;&gt;&#xD;&#xA;            &lt;li&gt;BP that is not below target despite receiving appropriate chronic antihypertensive therapy (&lt;strong&gt;Grade C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Symptoms suggestive of hypotension (&lt;strong&gt;Grade C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Fluctuating office BP readings (&lt;strong&gt;Grade D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;        &lt;li&gt;Physicians should use only ABPM devices that have been validated independently using established protocols (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Therapy adjustment should be considered in patients with a mean 24-hour ambulatory SBP of &amp;ge;130 mm Hg or DBP of &amp;ge;80 mm Hg or a mean awake SBP of &amp;ge;135 mm Hg or DBP of &amp;ge;85 mm Hg (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The magnitude of changes in nocturnal BP should be taken into account in any decision to prescribe or withhold drug therapy based on ABPM (&lt;strong&gt;Grade C&lt;/strong&gt;) because a decrease in nocturnal BP of &amp;lt;10% is associated with increased risk of cardiovascular events. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;9&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Role of Echocardiography&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Routine echocardiographic evaluation of all hypertensive patients is not recommended (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;An echocardiogram for assessment of left ventricular hypertrophy is useful in selected cases to help define the future risk of cardiovascular events (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Echocardiographic assessment of left ventricular mass, and of systolic and diastolic left ventricular function is recommended for hypertensive patients suspected to have left ventricular dysfunction or coronary artery disease (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients with hypertension and evidence of heart failure should have an objective assessment of left ventricular ejection fraction, either by echocardiogram or nuclear imaging (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Prevention and Treatment Recommendations&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Health Behavior Management&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Physical Exercise&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;For nonhypertensive or stage 1 hypertensive individuals, the use of resistance or weight training exercise (such as free weight lifting, fixed-weight lifting, or handgrip exercise) does not adversely influence BP (&lt;strong&gt;Grade D&lt;/strong&gt;) (&lt;strong&gt;new recommendation&lt;/strong&gt;). For nonhypertensive individuals (to reduce the possibility of becoming hypertensive) or for hypertensive patients (to reduce their BP), prescribe the accumulation of 30-60 minutes of moderate intensity dynamic exercise (e.g., walking, jogging, cycling, or swimming) 4-7 days per week in addition to the routine activities of daily living (&lt;strong&gt;Grade D&lt;/strong&gt;). Higher intensities of exercise are not more effective (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Weight Reduction&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;Height, weight, and waist circumference should be measured and body mass index calculated for all adults (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Maintenance of a healthy body weight (body mass index 18.5-24.9, and waist circumference &amp;lt;102 cm for men and &amp;lt;88 cm for women) is recommended for nonhypertensive individuals to prevent hypertension (&lt;strong&gt;Grade C&lt;/strong&gt;) and for hypertensive patients to reduce BP (&lt;strong&gt;Grade B&lt;/strong&gt;). All overweight hypertensive individuals should be advised to lose weight (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Weight loss strategies should employ a multidisciplinary approach that includes dietary education, increased physical activity, and behavioral intervention (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Alcohol Consumption&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;To reduce BP, alcohol consumption should be in accordance with Canadian low-risk drinking guidelines in normotensive and hypertensive individuals. Healthy adults should limit alcohol consumption to &amp;le;2 drinks per day, and consumption should not exceed 14 standard drinks per week for men and 9 standard drinks per week for women (&lt;strong&gt;Grade B&lt;/strong&gt;). (Note: 1 standard drink is considered to be equivalent of 13.6 g or 17.2 mL of ethanol or approximately 44 mL [1.5 oz] of 80 proof [40%] spirits, 355 mL [12 oz] of 5% beer, or 148 mL [5 oz] of 12% wine). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Dietary Recommendations&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;It is recommended that hypertensive patients and normotensive individuals at increased risk of developing hypertension consume a diet that emphasizes fruits, vegetables, low-fat dairy products, dietary and soluble fibre, whole grains, and protein from plant sources that is reduced in saturated fat and cholesterol (&lt;strong&gt;D&lt;/strong&gt;ietary &lt;strong&gt;A&lt;/strong&gt;pproaches to &lt;strong&gt;S&lt;/strong&gt;top &lt;strong&gt;H&lt;/strong&gt;ypertension [DASH] diet) (Sacks et al., 2001; Moore et al., 1999; Karanja et al., 1999; Appel et al., 1997). See Supplemental Table S9 (see the &quot;Availability of Companion Documents&quot; field) (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Sodium Intake&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;For prevention and treatment of hypertension, a dietary sodium intake of 1500 mg (65 mmol) per day is recommended for adults aged &amp;le;50 years; 1300 mg (57 mmol) per day for age 51-70 years; and 1200 mg (52 mmol) per day for age &amp;gt;70 years (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Potassium, Calcium, and Magnesium Intake&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;Supplementation of potassium, calcium, and magnesium is not recommended for the prevention or treatment of hypertension (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;7&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Stress Management&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;In hypertensive patients in whom stress might be contributing to BP elevation, stress management should be considered as an intervention (&lt;strong&gt;Grade D&lt;/strong&gt;). Individualized cognitive-behavioral interventions are more likely to be effective when relaxation techniques are used (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Indications for Drug Therapy for Adults with Hypertension without Compelling Indications for Specific Agents&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Antihypertensive therapy should be prescribed for average DBP measurements of &amp;ge;100 mm Hg (&lt;strong&gt;Grade A&lt;/strong&gt;) or average SBP measurements of &amp;ge;160 mm Hg (&lt;strong&gt;Grade A&lt;/strong&gt;) in patients without macrovascular target organ damage or other cardiovascular risk factors. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antihypertensive therapy should be strongly considered if DBP readings average &amp;ge;90 mm Hg in the presence of macrovascular target organ damage or other independent cardiovascular risk factors (&lt;strong&gt;Grade A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antihypertensive therapy should be strongly considered if SBP readings average &amp;ge;140 mm Hg in the presence of macrovascular target organ damage (&lt;strong&gt;Grade C for 140-160 mm Hg; Grade A for &amp;gt;160 mm Hg&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antihypertensive therapy should be considered in all patients meeting indications 1-3 in this section, regardless of age (&lt;strong&gt;Grade B&lt;/strong&gt;). Caution should be exercised in elderly patients who are frail. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Choice of Therapy for Adults with Hypertension without Compelling Indications for Specific Agents&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Recommendations for Individuals with Diastolic and/or Systolic Hypertension&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;Initial therapy should be monotherapy with a thiazide diuretic (&lt;strong&gt;Grade A&lt;/strong&gt;), a &amp;beta;-blocker (in patients younger than 60 years;&lt;strong&gt; Grade B&lt;/strong&gt;), an ACE inhibitor (in nonblack patients; &lt;strong&gt;Grade B&lt;/strong&gt;), a long-acting calcium channel blocker (CCB) (&lt;strong&gt;Grade B&lt;/strong&gt;); or an ARB (&lt;strong&gt;Grade B&lt;/strong&gt;). If there are adverse effects, another drug from this group should be substituted. Hypokalemia should be avoided in patients treated with thiazide diuretic agents alone (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Additional antihypertensive drugs should be used if target BP levels are not achieved with standard-dose monotherapy (&lt;strong&gt;Grade B&lt;/strong&gt;). Add-on drugs should be chosen from first-line choices. Useful choices include a thiazide diuretic or CCB with either: ACE inhibitor, ARB, or &amp;beta;-blocker (&lt;strong&gt;Grade B for the combination of thiazide diuretic and a dihydropyridine CCB; Grade C for the combination of dihydropyridine CCB and ACE inhibitor; and Grade D for all other combinations&lt;/strong&gt;). Caution should be exercised in combining a nondihydropyridine CCB and a &amp;beta;-blocker (&lt;strong&gt;Grade D&lt;/strong&gt;). The combination of an ACE inhibitor and an ARB is not recommended (&lt;strong&gt;Grade A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Combination therapy using 2 first-line agents might also be considered as initial treatment of hypertension (&lt;strong&gt;Grade C&lt;/strong&gt;) if SBP is 20 mm Hg above target or if DBP is 10 mm Hg above target. However, caution should be exercised in patients in whom a substantial fall in BP from initial combination therapy is more likely to occur or in whom it would be poorly tolerated (e.g., elderly patients). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;If BP is still not controlled with a combination of 2 or more first-line agents, or there are adverse effects, other antihypertensive drugs may be added (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Possible reasons for poor response to therapy (see Supplemental Table S10 [see the &quot;Availability of Companion Documents&quot; field]) should be considered (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;&amp;alpha;-Blockers are not recommended as first-line agents for uncomplicated hypertension (&lt;strong&gt;Grade A&lt;/strong&gt;); &amp;beta;-blockers are not recommended as first-line therapy for uncomplicated hypertension in patients 60 years of age or older (&lt;strong&gt;Grade A&lt;/strong&gt;); and ACE inhibitors are not recommended as first-line therapy for uncomplicated hypertension in black patients (&lt;strong&gt;Grade A&lt;/strong&gt;). However, these agents may be used in patients with certain comorbid conditions or in combination therapy. &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Recommendations for Individuals with Isolated Systolic Hypertension&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;In the very elderly (age 80 years and older), the target for SBP should be &amp;lt;150 mm Hg (&lt;strong&gt;Grade C&lt;/strong&gt;) (&lt;strong&gt;new recommendation&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Initial therapy should be monotherapy with a thiazide diuretic (&lt;strong&gt;Grade A&lt;/strong&gt;), a long-acting dihydropyridine CCB (&lt;strong&gt;Grade A&lt;/strong&gt;), or an ARB (&lt;strong&gt;Grade B&lt;/strong&gt;). If there are adverse effects, another drug from this group should be substituted. Hypokalemia should be avoided in patients treated with thiazide diuretic monotherapy (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Additional antihypertensive drugs should be used if target BP levels are not achieved with standard-dose monotherapy (&lt;strong&gt;Grade B&lt;/strong&gt;). Add-on drugs should be chosen from first-line options (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;If BP is still not controlled with a combination of 2 or more first-line agents, or there are adverse effects, other classes of drugs (such as &amp;alpha;-blockers, ACE inhibitors, centrally acting agents, or non-dihydropyridine CCBs) may be added or substituted (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Possible reasons for poor response to therapy (see Supplemental Table S10 [see the &quot;Availability of Companion Documents&quot; field]) should be considered (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;&amp;alpha;-Blockers are not recommended as first-line agents for uncomplicated isolated systolic hypertension (&lt;strong&gt;Grade A&lt;/strong&gt;); and &amp;beta;-blockers are not recommended as first-line therapy for isolated systolic hypertension in patients aged &amp;ge;60 years (&lt;strong&gt;Grade A&lt;/strong&gt;). However, both agents may be used in patients with certain comorbid conditions or in combination therapy. &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Global Vascular Protection Therapy for Adults with Hypertension without Compelling Indications for Specific Agents&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Statin therapy is recommended in hypertensive patients with 3 or more cardiovascular risk factors as defined in Supplemental Table S11 (see the &quot;Availability of Companion Documents&quot; field) in the original guideline document (&lt;strong&gt;Grade A in patients &amp;gt;40 years&lt;/strong&gt;), or with established atherosclerotic disease (&lt;strong&gt;Grade A regardless of age&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Strong consideration should be given to the addition of low-dose acetylsalicylic acid therapy in hypertensive patients (&lt;strong&gt;Grade A in patients &amp;gt;50 years&lt;/strong&gt;). Caution should be exercised if BP is not controlled (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Goal of Therapy for Adults with Hypertension without Compelling Indications for Specific Agents&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;The SBP treatment goal is a pressure level of &amp;lt;140 mm Hg (&lt;strong&gt;Grade C&lt;/strong&gt;). The DBP treatment goal is a pressure level of &amp;lt;90 mm Hg (&lt;strong&gt;Grade A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Treatment of Hypertension in Association with Ischemic Heart Disease&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Recommendations for Hypertensive Patients with Coronary Artery Disease&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;An ACE inhibitor or ARB is recommended for most patients with hypertension and coronary artery disease (&lt;strong&gt;Grade A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For patients with stable angina, &amp;beta;-blockers are preferred as initial therapy (&lt;strong&gt;Grade B&lt;/strong&gt;). CCBs may also be used (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Short-acting nifedipine should not be used (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For patients with coronary artery disease, but without coexisting systolic heart failure, the combination of an ACE inhibitor and ARB is not recommended (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;In high-risk patients, when combination therapy is being used, choices should be individualized. The combination of an ACE inhibitor and a dihydropyridine CCB is preferable to an ACE inhibitor and a diuretic in selected patients (&lt;strong&gt;Grade&lt;/strong&gt; &lt;strong&gt;A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;Recommendations for Patients with Hypertension Who Have Had a Recent Myocardial Infarction&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;Initial therapy should include both a &amp;beta;-blocker and an ACE inhibitor (&lt;strong&gt;Grade A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;An ARB can be used if the patient is intolerant of an ACE inhibitor (&lt;strong&gt;Grade A in patients with left ventricular systolic dysfunction&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;CCBs may be used in patients after myocardial infarction when &amp;beta;-blockers are contraindicated or not effective. Nondihydropyridine CCBs should not be used when there is heart failure, as evidenced by pulmonary congestion on examination or radiography (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;7&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Treatment of Hypertension in Association with Heart Failure&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;In patients with systolic dysfunction (ejection fraction &amp;lt;40%), ACE inhibitors (&lt;strong&gt;Grade&lt;/strong&gt; &lt;strong&gt;A&lt;/strong&gt;) and &amp;beta;-blockers (&lt;strong&gt;Grade A&lt;/strong&gt;) are recommended for initial therapy. Aldosterone antagonists (mineralocorticoid receptor antagonists) may be added for patients with a recent cardiovascular hospitalization, acute myocardial infarction, elevated B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide level, or New York Heart Association class II to IV symptoms (&lt;strong&gt;Grade A&lt;/strong&gt;). Careful monitoring for hyperkalemia is recommended when adding an aldosterone antagonist to ACE inhibitor or ARB therapy. Other diuretics are recommended as additional therapy if needed (&lt;strong&gt;Grade B for thiazide diuretics for BP control, Grade D for loop diuretics for volume control&lt;/strong&gt;). Beyond considerations of BP control, doses of ACE inhibitors or ARBs should be titrated to those found to be effective in trials unless adverse effects become manifest (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;An ARB is recommended if ACE inhibitors are not tolerated (&lt;strong&gt;Grade A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;A combination of hydralazine and isosorbide dinitrate is recommended if ACE inhibitors and ARBs are contraindicated or not tolerated (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;For hypertensive patients whose BP is not controlled, an ARB may be added to an ACE inhibitor and other antihypertensive drug treatment (&lt;strong&gt;Grade A&lt;/strong&gt;). Careful monitoring should be used if combining an ACE inhibitor and an ARB because of potential adverse effects such as hypotension, hyperkalemia, and worsening renal function (&lt;strong&gt;Grade C&lt;/strong&gt;). Additional therapies might also include dihydropyridine CCBs (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;8&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Treatment of Hypertension in Association with Stroke&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;BP Management in Acute Stroke (Onset to 72 Hours)&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;For patients with ischemic stroke not eligible for thrombolytic therapy, treatment of hypertension in the setting of acute ischemic stroke or transient ischemic attack should not be routinely undertaken (&lt;strong&gt;Grade D&lt;/strong&gt;). Extreme BP elevation (e.g., SBP &amp;gt;220 mm Hg or DBP &amp;gt;120 mm Hg) may be treated to reduce the BP by approximately 15% (&lt;strong&gt;Grade D&lt;/strong&gt;), and not more than 25%, over the first 24 hours with gradual reduction thereafter (&lt;strong&gt;Grade D&lt;/strong&gt;). Avoid excessive lowering of BP because this might exacerbate existing ischemia or might induce ischemia, particularly in the setting of intracranial arterial occlusion or extracranial carotid or vertebral artery occlusion (&lt;strong&gt;Grade D&lt;/strong&gt;). Pharmacological agents and routes of administration should be chosen to avoid precipitous falls in BP (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For patients with ischemic stroke eligible for thrombolytic therapy, very high BP (&amp;gt;185/110 mm Hg) should be treated concurrently in patients receiving thrombolytic therapy for acute ischemic stroke to reduce the risk of secondary intracranial hemorrhage (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: upper-alpha;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;em&gt;BP Management after Acute Stroke&lt;/em&gt;&#xD;&#xA;        &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;            &lt;li&gt;Strong consideration should be given to the initiation of antihypertensive therapy after the acute phase of a stroke or transient ischemic attack (&lt;strong&gt;Grade A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;After the acute phase of a stroke, BP-lowering treatment is recommended to a target of BP consistently &amp;lt;140/90 mm Hg (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Treatment with an ACE inhibitor and/or diuretic combination is preferred (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For patients with stroke, the combination of an ACE inhibitor and ARB is not recommended (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;/ol&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;9&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Treatment of Hypertension in Association with Left Ventricular Hypertrophy&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Hypertensive patients with left ventricular hypertrophy should be treated with antihypertensive therapy to lower the rate of subsequent cardiovascular events (&lt;strong&gt;Grade C&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The choice of initial therapy can be influenced by the presence of left ventricular hypertrophy (&lt;strong&gt;Grade D&lt;/strong&gt;). Initial therapy can be drug treatment using ACE inhibitors, ARBs, long-acting CCBs, or thiazide diuretics. Direct arterial vasodilators such as hydralazine or minoxidil should not be used. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;10&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Treatment of Hypertension in Association with Nondiabetic CKD&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;For patients with nondiabetic CKD, target BP is &amp;lt;140/90 mm Hg (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;For patients with hypertension and proteinuric CKD (urinary protein &amp;gt;500 mg per 24 hours or albumin-to-creatinine ratio &amp;gt;30 mg/mmol), initial therapy should be an ACE inhibitor (&lt;strong&gt;Grade A&lt;/strong&gt;) or an ARB if there is intolerance to ACE inhibitors (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Thiazide diuretics are recommended as additive antihypertensive therapy (&lt;strong&gt;Grade D&lt;/strong&gt;). For patients with CKD and volume overload, loop diuretics are an alternative (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;In most cases, combination therapy with other antihypertensive agents might be needed to reach target BP levels (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The combination of an ACE inhibitor and ARB is not recommended for patients with nonproteinuric CKD (&lt;strong&gt;Grade B&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;11&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Treatment of Hypertension in Association with Renovascular Disease&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Renovascular hypertension should be treated in the same manner as hypertension without compelling indications, except for caution in the use of ACE inhibitors or ARBs because of the risk of acute renal failure in bilateral disease or unilateral disease with a solitary kidney (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Close follow-up and early intervention (angioplasty and stenting or surgery) should be considered for patients with uncontrolled hypertension despite therapy with &amp;ge;3 drugs, deteriorating kidney function, bilateral atherosclerotic renal artery lesions (or tight atherosclerotic stenosis in a single kidney), or recurrent episodes of flash pulmonary edema (&lt;strong&gt;Grade D&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;12&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Treatment of Hypertension in Association with Diabetes Mellitus&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Persons with diabetes mellitus should be treated to attain SBPs of &amp;lt;130 mm Hg (&lt;strong&gt;Grade C&lt;/strong&gt;) and DBPs of &amp;lt;80 mm Hg (&lt;strong&gt;Grade A&lt;/strong&gt;). (These target BP levels are the same as the BP treatment thresholds.) Combination therapy using 2 first-line agents might also be considered as initial treatment of hypertension (&lt;strong&gt;Grade B&lt;/strong&gt;) if SBP is 20 mm Hg above target or if DBP is 10 mm Hg above target. However, caution should be exercised in patients in whom a substantial fall in BP is more likely or poorly tolerated (e.g., elderly patients and patients with autonomic neuropathy). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;For persons with cardiovascular or kidney disease, including microalbuminuria or with cardiovascular risk factors in addition to diabetes and hypertension, an ACE inhibitor or an ARB is recommended as initial therapy (&lt;strong&gt;Grade A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;For persons with diabetes and hypertension not included in the previous recommendation, appropriate choices include (in alphabetical order): ACE inhibitors (&lt;strong&gt;Grade A&lt;/strong&gt;), ARBs (&lt;strong&gt;Grade B&lt;/strong&gt;), dihydropyridine CCBs (&lt;strong&gt;Grade A&lt;/strong&gt;), and thiazide/thiazide-like diuretics (&lt;strong&gt;Grade A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If target BP levels are not achieved with standard-dose monotherapy, additional antihypertensive therapy should be used. For persons in whom combination therapy with an ACE inhibitor is being considered, a dihydropyridine CCB is preferable to hydrochlorothiazide (&lt;strong&gt;Grade A&lt;/strong&gt;). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;13&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Adherence Strategies for Patients&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Adherence to an antihypertensive prescription can be improved by a multipronged approach (see Supplemental Table S12 [see the &quot;Availability of Companion Documents&quot; field]). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-roman;&quot; start=&quot;14&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Treatment of Secondary Hypertension Due to Endocrine Causes&lt;/strong&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;        &lt;li&gt;Treatment of hyperaldosteronism and pheochromocytoma are outlined in Supplemental Tables S13 and S14 (see the &quot;Availability of Companion Documents&quot; field). &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grading Scheme for Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grading Scheme for Recommendations&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade A&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendations are based on randomized trials (or systematic reviews of trials) with high levels of internal validity and statistical precision, and for which the study results can be directly applied to patients because of similar clinical characteristics and the clinical relevance of the study outcomes.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade B&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendations are based on randomized trials, systematic reviews or prespecified subgroup analyses of randomized trials that have lower precision, or there is a need to extrapolate from studies because of differing populations or reporting of validated intermediate/surrogate outcomes rather than clinically important outcomes.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade C&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendations are based on trials that have lower levels of internal validity and/or precision, or trials reporting unvalidated surrogate outcomes, or results from non-randomized observational studies.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade D&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Recommendations are based on expert opinion alone.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An algorithm for the expedited assessment and diagnosis of patients with hypertension with a focus on validated technologies for blood pressure assessment is provided in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997 Apr 17;336(16):1117-24. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9099655&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Karanja NM, Obarzanek E, Lin PH, McCullough ML, Phillips KM, Swain JF, Champagne CM, Hoben KP. Descriptive characteristics of the dietary patterns used in the Dietary Approaches to Stop Hypertension Trial. DASH Collaborative Research Group. J Am Diet Assoc. 1999 Aug;99(8 Suppl):S19-27. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10450290&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Moore TJ, Vollmer WM, Appel LJ, Sacks FM, Svetkey LP, Vogt TM, Conlin PR, Simons-Morton DG, Carter-Edwards L, Harsha DW. Effect of dietary patterns on ambulatory blood pressure: results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. Hypertension. 1999 Sep;34(3):472-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10489396&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3-10. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11136953&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Improved hypertension prevention, detection, and management in the Canadian population&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of antihypertensive medications &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Careful monitoring should be used if combining an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin-receptor blocker (ARB) because of potential adverse effects such as hypotension, hyperkalemia, and worsening renal function. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Refer to Table 1 in the original guideline document for additional cautions concerning antihypertensive therapy.&lt;/p&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Nondihydropyridine calcium channel blockers (CCBs) should not be used when there is heart failure, as evidenced by pulmonary congestion on examination or radiography. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Direct arterial vasodilators such as hydralazine or minoxidil should not be used by the presence of left ventricular hypertrophy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment of hypertension should not be routinely undertaken in acute stroke unless extreme blood pressure (BP) elevation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoid angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARB) if bilateral renal artery stenosis or unilateral disease with solitary kidney. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Although individual antihypertensive agents might be mentioned when discussing evidence, the reader should presume the existence of a class effect unless otherwise stated. In addition, these recommendations are intended as a guide for health care practitioners and should not replace sound clinical judgement. They also do not take economic considerations into account. Health care providers are also advised to consider patient preferences when applying these recommendations to their patients.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The implementation task force conducts an extensive knowledge translation effort to enhance uptake and applicability of these recommendations. These efforts include knowledge exchange forums, targeted educational materials for primary care providers and patients, and freely available slide kits and summary documents of all recommendations on the &lt;a href=&quot;http://www.hypertension.ca&quot; title=&quot;Canadian Hypertension Society Web site&quot;&gt;Canadian Hypertension Society Web site&lt;/a&gt;. Documents are available in French and English, and some documents are translated into other languages. The Canadian Hypertension Education Program (CHEP) outcomes task force conducts hypertension surveillance studies and reviews existing Canadian health surveys to identify gaps between current and best practices. The implementation task force also regularly receives feedback from end users to improve guideline processes and content. Although the number of primary care providers that directly receive CHEP materials on a regular basis has dramatically increased, CHEP is continuing to address the challenge of identifying and reaching all active primary care providers across Canada, through use of the hypertension.ca website, &quot;Train the Trainer&quot; teaching sessions, and wide dissemination of educational materials.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Foreign Language Translations" /><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /><FieldValue Value="Slide Presentation" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, Khan NA, Herman RJ, Bacon SL, Cloutier L, Dawes M, Rabkin SW, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Feldman RD, Lindsay P, Hill MD, Gelfer M, Burns KD, Vallee M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Sharma M, Reid DJ, Tobe SW, Poirier L, Padwal RS, Canadian Hypertension Education Program. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2013 May;29(5):528-42. [38 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23541660&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2012 (revised 2013 May)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Canadian Cardiovascular Society - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Canadian Hypertension Education Program (CHEP) is operated and funded by Hypertension Canada. The members of the CHEP Committee are unpaid volunteers who contribute their time and expertise to the annual development and dissemination of the CHEP Recommendations. To maintain professional credibility of the content, the process for the development of the recommendations is fully independent and free from external influence. External partners assist with the dissemination of the approved recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Canadian Hypertension Education Program (CHEP) Recommendations Task Force&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force Members&lt;/em&gt;: Daniel G. Hackam, MD, PhD, Division of Clinical Pharmacology, Departments of Medicine, Clinical Neurological Sciences, and Epidemiology and Biostatistics, Western University, London, Ontario, Canada; Robert R. Quinn, MD, PhD, Division of Nephrology, Department of Medicine, and Department of Community Health Sciences, Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada; Pietro Ravani, MD, PhD, Division of Nephrology, Department of Medicine, and Department of Community Health Sciences, Foothills Medical Centre, University of Calgary, Calgary, Alberta, Canada; Doreen M. Rabi, MD, MSc, Departments of Medicine, Community Health and Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada; Kaberi Dasgupta, MD, MSc, Divisions of General Internal Medicine, Clinical Epidemiology and Endocrinology, Department of Medicine, McGill University, McGill University Health Centre, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; Stella S. Daskalopoulou, MD, PhD, Divisions of General Internal Medicine, Clinical Epidemiology and Endocrinology, Department of Medicine, McGill University, McGill University Health Centre, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; Nadia A. Khan, MD, MSc, Division of General Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Robert J. Herman, MD, University of Calgary, Calgary, Alberta, Canada; Simon L. Bacon, PhD, Concordia University, H&amp;ocirc;pital du Sacr&amp;eacute;-Coeur de Montr&amp;eacute;al, Montr&amp;eacute;al Heart Institute, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; Lyne Cloutier, RN, PhD, Universit&amp;eacute; du Qu&amp;eacute;bec &amp;agrave; Trois-Rivi&amp;egrave;res, Trois-Rivi&amp;egrave;res, Qu&amp;eacute;bec, Canada; Martin Dawes, MBBS, MD(Lond), University of British Columbia, Vancouver, British Columbia, Canada; Simon W. Rabkin, MD, Vancouver Hospital, University of British Columbia, Vancouver, British Columbia, Canada; Richard E. Gilbert, MD, PhD, Division of Endocrinology, University of Toronto, St Michael's Hospital, Toronto, Ontario, Canada; Marcel Ruzicka, MD, PhD, Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada; Donald W. McKay, PhD, Faculty of Medicine, Memorial University of Newfoundland, St John's, Newfoundland and Labrador, Canada; Tavis S. Campbell, PhD, Department of Psychology, University of Calgary, Calgary, Alberta, Canada; Steven Grover, MD, MPA, Division of Clinical Epidemiology, Montr&amp;eacute;al General Hospital, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; George Honos, MD, University of Montr&amp;eacute;al, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; Ernesto L. Schiffrin, MD, PhD, Department of Medicine and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; Peter Bolli, MD, Ambulatory Internal Medicine Teaching Clinic, St Catharines, Ontario, Canada; Thomas W. Wilson, MD, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; Ross D. Feldman, MD, Western University, London, Ontario, Canada; Patrice Lindsay, RN, BScN, MEd, PhD, Canadian Stroke Network, Ottawa Hospital Research Institute, University of Toronto, Toronto, Ontario, Canada; Michael D. Hill, MD, MSc, Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; Mark Gelfer, MD, Department of Family Medicine, University of British Columbia, Copeman Healthcare Centre, Vancouver, British Columbia, Canada; Kevin D. Burns, MD, University of British Columbia, Vancouver, British Columbia, Canada; Michel Vall&amp;eacute;e, MD, PhD, H&amp;ocirc;pital Maisonneuve-Rosemont, Universit&amp;eacute; de Montr&amp;eacute;al, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; G.V. Ramesh Prasad, MBBS, MSc, University of Toronto, Toronto, Ontario, Canada; Marcel Lebel, MD, Department of Medicine, Universit&amp;eacute; Laval, Qu&amp;eacute;bec City, Qu&amp;eacute;bec, Canada; Donna McLean, RN, NP, PhD, University of Alberta, Edmonton, Alberta, Canada; J. Malcolm O. Arnold, MD, Western University, London, Ontario, Canada; Gordon W. Moe, MD, MSc, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada; Jonathan G. Howlett, MD, Department of Medicine, University of Calgary, Calgary, Ontario, Canada; Jean-Martin Boulanger, MD, Charles LeMoyne Hospital Research Centre, Sherbrooke University, Sherbrooke, Qu&amp;eacute;bec, Canada; Pierre Larochelle, MD, Institut de Recherches Cliniques de Montr&amp;eacute;al, Universit&amp;eacute; de Montr&amp;eacute;al, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; Lawrence A. Leiter, MD, Keenan Research Centre in the Li Ka Shing Knowledge Institute of St Michael's Hospital, and University of Toronto, Toronto, Ontario, Canada; Charlotte Jones, MD, PhD, University of British Columbia, Vancouver, British Columbia, Canada; Richard I. Ogilvie, MD, University Health Network, Departments of Medicine and Pharmacology, University of Toronto, Toronto, Ontario, Canada; Vincent Woo, MD, University of Manitoba, Winnipeg, Manitoba, Canada; Janusz Kaczorowski, PhD, Universit&amp;eacute; de Montr&amp;eacute;al and CHUM, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; Luc Trudeau, MD, Division of Internal Medicine, McGill University, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; Robert J. Petrella, MD, PhD, Department of Family Medicine, Western University, London, Ontario, Canada; Alain Milot, MD, MSc, Department of Medicine, Universit&amp;eacute; Laval, Qu&amp;eacute;bec City, Qu&amp;eacute;bec, Canada; James A. Stone, MD, PhD, Division of Cardiology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Denis Drouin, MD, Faculty of Medicine, Universit&amp;eacute; Laval, Qu&amp;eacute;bec, Qu&amp;eacute;bec, Canada; Kim L. Lavoie, PhD, Department of Psychology, University of Qu&amp;eacute;bec at Montr&amp;eacute;al (UQAM), Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; Maxime Lamarre-Cliche, MD, Institut de Recherches Cliniques de Montr&amp;eacute;al, Universit&amp;eacute; de Montr&amp;eacute;al, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; Marshall Godwin, MD, MSc, Memorial University of Newfoundland, St John's, Newfoundland and Labrador, Canada; Guy Tremblay, MD, CHU-Qu&amp;eacute;bec-H&amp;ocirc;pital St. Sacrement, Qu&amp;eacute;bec City, Qu&amp;eacute;bec, Canada; Pavel Hamet, MD, PhD, Facult&amp;eacute; de M&amp;eacute;dicine, Universit&amp;eacute; de Montr&amp;eacute;al, Montr&amp;eacute;al, Qu&amp;eacute;bec, Canada; George Fodor, MD, PhD, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; S. George Carruthers, MD, Lisburn, Northern Ireland; George B. Pylypchuk, MD, Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; Ellen Burgess, MD, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada; Richard Lewanczuk, MD, PhD, University of Alberta, Edmonton, Alberta, Canada; George K. Dresser, MD, PhD, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; S. Brian Penner, MD, Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; Robert A. Hegele, MD, Departments of Medicine (Division of Endocrinology) and Biochemistry, Western University, London, Ontario, Canada; Philip A. McFarlane, MD, PhD, Division of Nephrology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada; Mukul Sharma, MD, MSc, The Canadian Stroke Network, Ottawa, Ontario, Canada; Debra J. Reid, PhD, RD, Canadian Forces Health Services, Department of National Defence and Dietitians of Canada, Ottawa, Ontario, Canada; Sheldon W. Tobe, MD, University of Toronto, Toronto, Ontario, Canada; Luc Poirier, BPharm, MSc, Centre Hospitalier Universitaire de Qu&amp;eacute;bec et Facult&amp;eacute; de Pharmacie, Universit&amp;eacute; Laval, Qu&amp;eacute;bec City, Qu&amp;eacute;bec, Canada; Raj S. Padwal, MD, MSc, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Conflicts of interest have been reported in &lt;a href=&quot;http://www.onlinecjc.ca/article/PIIS0828282X13000263/attachment?filename=mmc1.pdf&quot; title=&quot;Canadian Journal of Cardiology Web site&quot;&gt;Supplemental Appendix S2&lt;/a&gt; in the supplemental materials.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Daskalopoulou SS, Khan NA, Quinn RR, et al. The 2012 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2012;28:270-87.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.onlinecjc.ca/article/S0828-282X(13)00026-3/fulltext&quot; title=&quot;Canadian Journal of Cardiology Web site&quot;&gt;Canadian Journal of Cardiology Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Supplemental material, including tables, is available from the &lt;a href=&quot;http://www.onlinecjc.ca/article/S0828-282X(13)00026-3/addOns&quot; title=&quot;Canadian Journal of Cardiology Web site&quot;&gt;Canadian Journal of Cardiology Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A variety of resources, including key messages, a one-page summary, slide sets, and resources for managing and measuring blood pressure, sodium, and hypertension and diabetes are available in &lt;a href=&quot;http://www.hypertension.ca/resources&quot; title=&quot;Canadian Hypertension Society Web site&quot;&gt;English&lt;/a&gt; and &lt;a href=&quot;http://www.hypertension.ca/fr/ressources&quot; title=&quot;Canadian Hypertension Society Web site&quot;&gt;French&lt;/a&gt; from the Canadian Hypertension Society Web site.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A variety of patient resources are available in &lt;a href=&quot;http://www.hypertension.ca/public&quot; title=&quot;Canadian Hypertension Society Web site&quot;&gt;English&lt;/a&gt; and &lt;a href=&quot;http://www.hypertension.ca/fr/public&quot;&gt;French&lt;/a&gt; from the Canadian Hypertension Society Web site.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on September 10, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
